Affiliation:
1. Yale University, School of Medicine, Section of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine, New Haven, CT, USA
Abstract
Introduction Asthma is a common childhood condition. Up until recent years, the mainstay of long-term control treatment has been inhaled corticosteroids. While inhaled corticosteroids are very effective for most children with asthma, with the introduction of biologic therapies, additional options now exist for children with uncontrolled moderate to severe asthma. Purpose The purpose of this Practice Update is to provide nursing professionals with a summary of the biologic therapies currently available for the pediatric population and, to describe when they are indicated for inclusion in the plan of care for children with moderate to severe asthma. Conclusion By properly diagnosing asthma, and, selecting and administering appropriate asthma therapies, nursing professionals can help children with moderate to severe asthma lead healthy and active lives.
Reference18 articles.
1. AstraZeneca (2021a). Benralizumab: Fasenra prescribing information. AstraZeneca.
2. AstraZeneca. (2021b). Tezepelumab: Tezspire full prescribing information. AstraZeneca.
3. Which Child with Asthma is a Candidate for Biological Therapies?
4. Centers for Disease Control and Prevention (CDC) (N.D.a). Asthma-related missed school days among children aged 5–17 years. https://www.cdc.gov/asthma/asthma_stats/missing_days.htm
5. Centers for Disease Control and Prevention (CDC) (N.D.b). Asthma severity among children with current asthma. https://www.cdc.gov/asthma/asthma_stats/severity_child.htm
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献